ELOXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:14):

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases...

Stats
本日の出来高	15 960.00
平均出来高	7 581.00
時価総額	2.83M
EPS	$0 ( 2024-04-01 )
次の収益日	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.100
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-24	Walts Alan Edmund	Buy	7 500	Restricted Stock Units
2024-01-24	Rubin Steven D	Buy	7 500	Restricted Stock Units
2024-01-24	Androski Lindsay	Buy	7 500	Restricted Stock Units
2024-01-24	Aggarwal Sumit	Buy	60 000	Restricted Stock Units
2023-01-30	Walts Alan Edmund	Buy	2 859	Stock Options (Right to Buy)

INSIDER POWER
100.00
Last 94 transactions
Buy: 28 846 630 \| Sell: 836 099

Eloxx Pharmaceuticals Inc 相関

10 最も正の相関
PAIC	0.954
SVAC	0.941
RMRM	0.917
MTSL	0.873
CASI	0.869
TLGT	0.866
AGMH	0.861
BLKB	0.857
SVOK	0.855
KC	0.851

10 最も負の相関
NETE	-0.961
MMAC	-0.934
RAVN	-0.907
AMRB	-0.891
BOCH	-0.89
SHSP	-0.867
SRAC	-0.837
LWAC	-0.819
DFFN	-0.806

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Eloxx Pharmaceuticals Inc 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-16.65

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-16.65

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1 526.00

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1 378.77

Financial Reports:

No articles found.

Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.